Survivin is a negative prognostic factor in malignant pleural effusion.

Survivin is a negative prognostic factor in malignant pleural effusion. Eur J Clin Invest. 2018 Jan 23;: Authors: Arellano-Orden E, Romero-Romero B, Sánchez-López V, Martín-Juan J, Rodríguez-Panadero F, Otero-Candelera R Abstract SURVIVIN: is a well-known member of the inhibitor of apoptosis family, and has been related with increased tumour aggressivity, both in tissue and in pleural fluid. OBJECTIVES: In patients with malignant pleural effusion, we sought to investigate the changes in pleural fluid survivin concentrations induced by talc instillation into the pleural space. Those changes were also examined in relation to pleurodesis outcome and patient survival. METHODS: We investigated 84 patients with malignant pleural effusion who underwent talc pleurodesis. Of them, 32 had breast cancer, 25 lung cancer, and 27 mesothelioma. Serial samples of pleural fluid were obtained before thoracoscopy (baseline) and 24 h thereafter. RESULTS: Survivin levels were successfully quantified in all pleural fluid samples, and they were significantly higher in samples obtained after thoracoscopic talc poudrage compared with baseline (p
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Eur J Clin Invest Source Type: research

Related Links:

Abstract Locoregional recurrence negatively impacts both long-term survival and quality of life for several malignancies. For appropriate-risk patients with an isolated, resectable, local recurrence, surgery represents the only potentially curative therapy. However, oncologic outcomes remain inferior for patients with locally recurrent disease even after macroscopically complete resection. Unfortunately, these operations are often extensive, with significant perioperative morbidity and mortality. This review highlights selected malignancies (mesothelioma, sarcoma, lung cancer, breast cancer, rectal cancer, and per...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: CA Cancer J Clin Source Type: research
Thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering (MSK) Cancer Center believes customized gene therapy will soon change the way pleural mesothelioma is treated. Adusumilli, director of the Mesothelioma Program at MSK, has worked for a decade on developing tumor immunology for thoracic malignancies. He is currently the principal investigator of a phase I clinical trial involving specially prepared immune cells — chimeric antigen receptor (CAR) T cells — that have shown impressive efficacy with mesothelioma. “I think this is going to change the paradigm of treating mesotheliom...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Cardiac tumors have generally been considered to be rare. They are often found incidentally as they tend to remain clinically silent, but they can sometimes present with symptoms secondary to obstruction, embolization, or invasion of the myocardium. Most cardiac tumors are secondary tumors from metastases, with primary cardiac tumors constituting approximately 15% of all cardiac tumors1. Although melanoma and pleural mesothelioma often have cardiac involvement, the most common cancers to be identified in cardiac metastases are lung cancer (36-39%), breast cancer (10-12%), and hematologic cancers (10-21%)2.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Clinical Communication to the Editor Source Type: research
Cardiac tumors have generally been considered to be rare. They are often found incidentally, as they tend to remain clinically silent, but they can sometimes present with symptoms secondary to obstruction, embolization, or invasion of the myocardium. Most cardiac tumors are secondary tumors from metastases, with primary cardiac tumors constituting approximately 15% of all cardiac tumors.1 Although melanoma and pleural mesothelioma often have cardiac involvement, the most common cancers to be identified in cardiac metastases are lung cancer (36%-39%), breast cancer (10%-12%), and hematologic cancers (10%-21%).
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Clinical Communication to the Editor Source Type: research
Abstract Proteomics-based analyses are powerful means of identifying potentially useful proteins in the initial stage of drug development. Technological developments in the field of proteomics, and increases in the sensitivity of MS analyses, now facilitate identification and examination of increasingly small amounts of proteins that are differentially expressed in diseased versus normal tissues and can be candidate biomarkers or therapeutic targets. However, the current approach is for candidate proteins to be prioritized by research interest and then validated one by one; this is very inefficient. To address thi...
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Biol Pharm Bull Source Type: research
Immunotoxins (antibody conjugates) target cancer cells while allowing normal cells to survive.  As a result, patients receiving immunotoxins are less likely to experience the deleterious side-effects associated with non-specific therapies such as chemotherapy.  In order to make an effective immunotoxin, three components are generally required: a targeting domain, a toxic payload molecule su ch as Pseudomonas exotoxin A (PE), and a furin cleavage site (FCS).   The purpose of the FCS is to allow the toxin domain to be processed by the target cell so that it can exert its toxic effect.Researchers at the Nationa...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
The National Cancer Institute,Laboratory of Molecular Biologyseeks parties interested in collaborative research to further co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers. The antibody was able to inhibit tumor growth in mouse xenograft models, and corresponding immunotoxins were able to inhibit tumor cell growth in vitroMesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. This selective expression makes ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
CONCLUSIONS: The main cause of MPE in our setting was lung cancer, followed by breast cancer, unknown primary and mesothelioma. Chemical pleurodesis was a viable palliative measure for MPE in this population. PMID: 29629675 [PubMed - in process]
Source: South African Medical Journal - Category: African Health Tags: S Afr Med J Source Type: research
The second trial involving Johnson &Johnson’s iconic baby powder and its possible link to mesothelioma began this week in a Middlesex County, New Jersey, superior court. A jury in California two months ago — in a highly anticipated first trial — found the pharmaceutical giant was not responsible for a plaintiff’s mesothelioma, the rare asbestos-related cancer. Superior Court Judge Ana Viscomi opened the latest trial Monday in New Brunswick, New Jersey, just a few blocks from the world headquarters of Johnson &Johnson. The trial is estimated to last two months. Plaintiff Stephen Lanzo III, 46...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract Survivinis a well‐known member of the inhibitor of apoptosis family, and has been related with increased tumour aggressivity, both in tissue and in pleural fluid. ObjectivesIn patients with malignant pleural effusion, we sought to investigate the changes in pleural fluid survivin concentrations induced by talc instillation into the pleural space. Those changes were also examined in relation to pleurodesis outcome and patient survival. MethodsWe investigated 84 patients with malignant pleural effusion who underwent talc pleurodesis. Of them, 32 had breast cancer, 25 lung cancer, and 27 mesothelioma. Serial sample...
Source: European Journal of Clinical Investigation - Category: General Medicine Authors: Tags: Original Paper Source Type: research
More News: Asbestosis | Breast Cancer | Cancer | Cancer & Oncology | Lung Cancer | Mesothelioma